|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TP53INP1 |
Gene summary for TP53INP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TP53INP1 | Gene ID | 94241 |
| Gene name | tumor protein p53 inducible nuclear protein 1 | |
| Gene Alias | SIP | |
| Cytomap | 8q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000045 | UniProtAcc | Q96A56 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 94241 | TP53INP1 | P49T-E | Human | Esophagus | ESCC | 1.29e-04 | 5.65e-01 | 0.1768 |
| 94241 | TP53INP1 | P52T-E | Human | Esophagus | ESCC | 2.17e-02 | 2.94e-02 | 0.1555 |
| 94241 | TP53INP1 | P54T-E | Human | Esophagus | ESCC | 5.52e-08 | 2.90e-01 | 0.0975 |
| 94241 | TP53INP1 | P56T-E | Human | Esophagus | ESCC | 2.96e-02 | 3.41e-01 | 0.1613 |
| 94241 | TP53INP1 | P57T-E | Human | Esophagus | ESCC | 1.90e-05 | 5.91e-02 | 0.0926 |
| 94241 | TP53INP1 | P62T-E | Human | Esophagus | ESCC | 6.05e-09 | 2.47e-01 | 0.1302 |
| 94241 | TP53INP1 | P65T-E | Human | Esophagus | ESCC | 8.18e-03 | 6.73e-02 | 0.0978 |
| 94241 | TP53INP1 | P75T-E | Human | Esophagus | ESCC | 1.39e-16 | 3.43e-01 | 0.1125 |
| 94241 | TP53INP1 | P79T-E | Human | Esophagus | ESCC | 9.56e-06 | 9.28e-02 | 0.1154 |
| 94241 | TP53INP1 | P82T-E | Human | Esophagus | ESCC | 1.16e-04 | 3.37e-01 | 0.1072 |
| 94241 | TP53INP1 | P84T-E | Human | Esophagus | ESCC | 4.81e-02 | 2.12e-01 | 0.0933 |
| 94241 | TP53INP1 | P107T-E | Human | Esophagus | ESCC | 4.49e-02 | 3.86e-02 | 0.171 |
| 94241 | TP53INP1 | P127T-E | Human | Esophagus | ESCC | 2.89e-02 | 1.78e-01 | 0.0826 |
| 94241 | TP53INP1 | P128T-E | Human | Esophagus | ESCC | 5.53e-10 | 4.45e-01 | 0.1241 |
| 94241 | TP53INP1 | P130T-E | Human | Esophagus | ESCC | 4.10e-13 | 2.62e-01 | 0.1676 |
| 94241 | TP53INP1 | NAFLD1 | Human | Liver | NAFLD | 9.75e-03 | 2.30e-01 | -0.04 |
| 94241 | TP53INP1 | S43 | Human | Liver | Cirrhotic | 2.48e-16 | -7.75e-02 | -0.0187 |
| 94241 | TP53INP1 | HCC1_Meng | Human | Liver | HCC | 1.33e-64 | -7.28e-02 | 0.0246 |
| 94241 | TP53INP1 | HCC2_Meng | Human | Liver | HCC | 4.92e-18 | -2.62e-01 | 0.0107 |
| 94241 | TP53INP1 | cirrhotic1 | Human | Liver | Cirrhotic | 1.15e-06 | -2.39e-01 | 0.0202 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001623617 | Esophagus | ESCC | macroautophagy | 216/8552 | 291/18723 | 1.94e-23 | 4.57e-21 | 216 |
| GO:0009896111 | Esophagus | ESCC | positive regulation of catabolic process | 332/8552 | 492/18723 | 4.36e-23 | 9.22e-21 | 332 |
| GO:0006979111 | Esophagus | ESCC | response to oxidative stress | 303/8552 | 446/18723 | 7.15e-22 | 1.30e-19 | 303 |
| GO:0031331111 | Esophagus | ESCC | positive regulation of cellular catabolic process | 292/8552 | 427/18723 | 8.67e-22 | 1.53e-19 | 292 |
| GO:0062197111 | Esophagus | ESCC | cellular response to chemical stress | 234/8552 | 337/18723 | 5.37e-19 | 5.97e-17 | 234 |
| GO:001050617 | Esophagus | ESCC | regulation of autophagy | 220/8552 | 317/18723 | 6.72e-18 | 6.36e-16 | 220 |
| GO:000941113 | Esophagus | ESCC | response to UV | 115/8552 | 149/18723 | 3.29e-15 | 1.93e-13 | 115 |
| GO:0034599111 | Esophagus | ESCC | cellular response to oxidative stress | 197/8552 | 288/18723 | 3.76e-15 | 2.15e-13 | 197 |
| GO:000703314 | Esophagus | ESCC | vacuole organization | 127/8552 | 180/18723 | 1.04e-11 | 3.85e-10 | 127 |
| GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
| GO:003464413 | Esophagus | ESCC | cellular response to UV | 70/8552 | 90/18723 | 4.59e-10 | 1.20e-08 | 70 |
| GO:007121419 | Esophagus | ESCC | cellular response to abiotic stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
| GO:010400419 | Esophagus | ESCC | cellular response to environmental stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
| GO:007147816 | Esophagus | ESCC | cellular response to radiation | 122/8552 | 186/18723 | 3.07e-08 | 5.73e-07 | 122 |
| GO:190503712 | Esophagus | ESCC | autophagosome organization | 73/8552 | 103/18723 | 1.88e-07 | 2.93e-06 | 73 |
| GO:0009408110 | Esophagus | ESCC | response to heat | 77/8552 | 110/18723 | 2.01e-07 | 3.11e-06 | 77 |
| GO:000004513 | Esophagus | ESCC | autophagosome assembly | 69/8552 | 99/18723 | 1.10e-06 | 1.38e-05 | 69 |
| GO:004814414 | Esophagus | ESCC | fibroblast proliferation | 57/8552 | 81/18723 | 5.83e-06 | 6.03e-05 | 57 |
| GO:001050816 | Esophagus | ESCC | positive regulation of autophagy | 81/8552 | 124/18723 | 7.74e-06 | 7.65e-05 | 81 |
| GO:004814514 | Esophagus | ESCC | regulation of fibroblast proliferation | 56/8552 | 80/18723 | 9.08e-06 | 8.71e-05 | 56 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TP53INP1 | SNV | Missense_Mutation | novel | c.379N>T | p.Pro127Ser | p.P127S | Q96A56 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| TP53INP1 | SNV | Missense_Mutation | c.649N>A | p.Asp217Asn | p.D217N | Q96A56 | protein_coding | tolerated(0.13) | possibly_damaging(0.536) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| TP53INP1 | SNV | Missense_Mutation | novel | c.82N>T | p.Asp28Tyr | p.D28Y | Q96A56 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-OL-A6VQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TP53INP1 | insertion | Frame_Shift_Ins | novel | c.511_512insATCAGTG | p.Cys171TyrfsTer32 | p.C171Yfs*32 | Q96A56 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| TP53INP1 | insertion | Frame_Shift_Ins | novel | c.509_510insACCAATTGATAACCAATCACATAGTT | p.His170GlnfsTer35 | p.H170Qfs*35 | Q96A56 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| TP53INP1 | insertion | In_Frame_Ins | novel | c.139_140insTCTTCTTTCTCTTCATTTATACCC | p.Glu47delinsValPhePheLeuPheIleTyrThrGln | p.E47delinsVFFLFIYTQ | Q96A56 | protein_coding | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| TP53INP1 | SNV | Missense_Mutation | c.136N>A | p.Glu46Lys | p.E46K | Q96A56 | protein_coding | tolerated(0.12) | benign(0.049) | TCGA-FU-A3YQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| TP53INP1 | SNV | Missense_Mutation | novel | c.421N>T | p.Leu141Phe | p.L141F | Q96A56 | protein_coding | deleterious(0.02) | possibly_damaging(0.787) | TCGA-VS-A8QF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TP53INP1 | deletion | Frame_Shift_Del | novel | c.26_29delTTGT | p.Phe9TrpfsTer28 | p.F9Wfs*28 | Q96A56 | protein_coding | TCGA-VS-A959-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| TP53INP1 | SNV | Missense_Mutation | c.649N>A | p.Asp217Asn | p.D217N | Q96A56 | protein_coding | tolerated(0.13) | possibly_damaging(0.536) | TCGA-AA-3837-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |